Bringing COVID-19 vaccines to the public
Once a vaccine to prevent COVID-19 is approved, there will be logistics to consider. For example, who will receive the vaccine first, and how can the supply chain safely deliver the vaccine to 330 million Americans and potentially more than 7 billion people worldwide? In addition, multiple vaccines may be brought to market within weeks to months of each other, confusing consumers. On the Mayo Clinic Q&A podcast, Dr. Gregory Poland, an infectious diseases expert and head of Mayo Clinic's Vaccine Research Group, explains the challenges of rolling out a COVID-19 vaccine.
Audio is streamed directly from the publisher (traffic.megaphone.fm) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Once a vaccine to prevent COVID-19 is approved, there will be logistics to consider. For example, who will receive the vaccine first, and how can the supply chain safely deliver the vaccine to 330 million Americans and potentially more than 7 billion people worldwide? In addition, multiple vaccines may be brought to market within weeks to months of each other, confusing consumers.
On the Mayo Clinic Q&A podcast, Dr. Gregory Poland, an infectious diseases expert and head of Mayo Clinic's Vaccine Research Group, explains the challenges of rolling out a COVID-19 vaccine.
Research disclosures for Dr. Gregory Poland.
Advertising Inquiries: https://redcircle.com/brands
Privacy & Opt-Out: https://redcircle.com/privacy